The expression levels of prolyl oligopeptidase responds not only to neuroinflammation but also to systemic inflammation upon liver failure in rat models and cirrhotic patients

Journal of Neuroinflammation

Vicente Felipo¹  J. Arturo García-Horsman³  Hanan Ahabrach¹  Vicente Hernandez-Rabaza¹  Amparo Urios²  Carmina Montoliu²  Jofre Tenorio-Laranga³ 

[1] Laboratory of Neurobiology, Centro de Investigación Príncipe Felipe, Avd.Autopista del Saler 16, Valencia, 46012, Spain;Fundación Investigación Hospital Clínico Universitario, INCLIVA, Valencia, Spain;Real-time Imaging Laboratory, Divisions of Pharmacology and Toxicology and Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, Helsinki 00014, Finland

关键词: Liver failure;    Minimal hepatic encephalopathy;    Hepatic cirrhosis;    Prolyl oligopeptidase;   

Others  :  1228652
DOI  :  10.1186/s12974-015-0404-7

 received in 2014-12-19, accepted in 2015-09-23,  发布年份 2015

【 摘 要 】

Background

Liver failure in experimental animals or in human cirrhosis elicits neuroinflammation. Prolyl oligopeptidase (PREP) has been implicated in neuroinflammatory events in neurodegenerative diseases: PREP protein levels are increased in brain glial cells upon neuroinflammatory insults, but the circulating PREP activity levels are decreased in multiple sclerosis patients in a process probably mediated by bioactive peptides. In this work, we studied the variation of PREP levels upon liver failure and correlated it with several inflammatory markers to conclude on the relation of PREP with systemic and/or neuroinflammation.

Methods

PREP enzymatic activity and protein levels measured with immunological techniques were determined in the brain and plasma of rats with portacaval shunt (PCS) and after treatment with ibuprofen. Those results were compared with the levels of PREP measured in plasma from cirrhotic patients with or without minimal hepatic encephalopathy (MHE). Levels of several pro-inflammatory cytokines and those of NO/cGMP homeostasis metabolites were measured in PCS rats and cirrhotic patients to conclude on the role of PREP in inflammation.

Results

In PCA rats, we found that PREP levels are significantly increased in the hippocampus, striatum and cerebellum, that in the cerebellum the PREP increase was significantly found in the extracellular space and that the levels were restored to those measured in control rats after administration of an anti-inflammatory agent, ibuprofen. In cirrhotic patients, circulatory PREP activity was found to correlate to systemic and neuroinflammatory markers and had a negative correlation with the severity of the disease, although no clear relation to MHE.

Conclusions

These results support the idea that PREP levels could be used as indicators of cirrhosis severity in humans, and using other markers, it might contribute to assessing the level of neuroinflammation in those patients. This work reports, for the first time, that PREP is secreted to the extracellular space in the cerebellum most probably due to glial activation and supports the role of the peptidase in the inflammatory response.

【 授权许可】

   
2015 Tenorio-Laranga et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

Fig. 7.

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

Fig. 7.

【 参考文献 】

• [1]Frederick RT: Current concepts in the pathophysiology and management of hepatic encephalopathy. Gastroenterol Hepatol (N Y) 2011, 7(4):222-33.
• [2]Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR: Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol 2001, 16(5):531-5.
• [3]Romero-Gómez M, Boza F, García-Valdecasas MS, García E, Aguilar-Reina J: Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001, 96(9):2718-23.
• [4]Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT: Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002, 35(3):716-21.
• [5]Cauli O, Rodrigo R, Piedrafita B, Boix J, Felipo V: Inflammation and hepatic encephalopathy: ibuprofen restores learning ability in rats with portacaval shunts. Hepatology 2007, 46(2):514-9.
• [6]Rodrigo R, Cauli O, Gomez-Pinedo U, Agusti A, Hernandez-Rabaza V, Garcia-Verdugo JM, et al.: Hyperammonemia induces neuroinflammation that contributes to cognitive impairment in rats with hepatic encephalopathy. Gastroenterology 2010, 139(2):675-84.
• [7]Shawcross DL, Davies NA, Williams R, Jalan R: Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004, 40(2):247-54.
• [8]Montoliu C, Piedrafita B, Serra MA, del Olmo JA, Urios A, Rodrigo JM, et al.: IL-6 and IL-18 in blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy. J of Clin Gastroenterol 2009, 43(3):272-9.
• [9]Agusti A, Cauli O, Rodrigo R, Llansola M, Hernández-Rabaza V, Felipo V: p38 MAP kinase is a therapeutic target for hepatic encephalopathy in rats with portacaval shunts. Gut 2011, 60(11):1572-9.
• [10]Männistö PT, Venäläinen J, Jalkanen A, García-Horsman JA: Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders. Drug News Perspect 2007, 20(5):293-305.
• [11]García-Horsman JA, Männistö PT, Venäläinen JI: On the role of prolyl oligopeptidase in health and disease. Neuropeptides 2007, 41(1):1-24.
• [12]Myöhänen TT, García-Horsman JA, Tenorio-Laranga J, Männistö PT: Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mRNA, protein levels, and enzymatic activity. J Histochem Cytochem 2009, 57(9):831-48.
• [13]Myöhänen TT, Venäläinen JI, García-Horsman JA, Piltonen M, Männistö PT: Cellular and subcellular distribution of rat brain prolyl oligopeptidase and its association with specific neuronal neurotransmitters. J Comp Neurol 2008, 507(5):1694-708.
• [14]Myöhänen TT, Kääriäinen TM, Jalkanen AJ, Piltonen M, Männistö PT: Localization of prolyl oligopeptidase in the thalamic and cortical projection neurons: a retrograde neurotracing study in the rat brain. Neurosci Lett 2009, 450(2):201-5.
• [15]Moreno-Baylach MJ, Puttonen KA, Tenorio-Laranga J, Venäläinen JI, Storvik M, Forsberg MM, et al.: Prolyl endopeptidase is involved in cellular signalling in human neuroblastoma SH-SY5Y cells. Neurosignals 2011, 19(2):97-109.
• [16]Moreno-Baylach MJ, Felipo V, Männistö PT, García-Horsman JA: Expression and traffic of cellular prolyl oligopeptidase are regulated during cerebellar granule cell differentiation, maturation, and aging. Neuroscience 2008, 156(3):580-5.
• [17]Agirregoitia N, Casis L, Gil J, Ruiz F, Irazusta J: Ontogeny of prolyl endopeptidase and pyroglutamyl peptidase I in rat tissues. Regul Pept 2007, 139(1–3):52-8.
• [18]Hannula MJ, Männistö PT, Myöhänen TT: Sequential expression, activity and nuclear localization of prolyl oligopeptidase protein in the developing rat brain. Dev Neurosci 2011, 33(1):38-47.
• [19]Tenorio-Laranga J, Peltonen I, Keskitalo S, Duran-Torres G, Natarajan R, Mannisto PT, et al.: Alteration of prolyl oligopeptidase and activated alpha-2-macroglobulin in multiple sclerosis subtypes and in the clinically isolated syndrome. Biochem Pharmacol 2013, 85:1783-94.
• [20]Penttinen A, Tenorio-Laranga J, Siikanen A, Morawski M, Rossner S, García-Horsman JA: Prolyl oligopeptidase: a rising star on the stage of neuroinflammation research. CNS Neurol Disord Drug Targets 2011, 10(3):340-8.
• [21]Gaggar A, Rowe SM, Matthew H, Blalock JE: Proline-Glycine-Proline (PGP) and High Mobility Group Box Protein-1 (HMGB1): potential mediators of cystic fibrosis airway inflammation. Open Respir Med J 2010, 4:32-8.
• [22]Hannula MJ, Myohanen TT, Tenorio-Laranga J, Mannisto PT, Garcia-Horsman JA: Prolyl oligopeptidase colocalizes with alpha-synuclein, beta-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases. Neuroscience 2013, 242:140-50.
• [23]Myöhänen TT, Hannula MJ, Van Elzen R, Gerard M, Van Der Veken P, García-Horsman JA, et al.: A prolyl oligopeptidase inhibitor, KYP-2047, reduces alpha-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease. Br J Pharmacol 2012, 166(3):1097-113.
• [24]Dokleja L, Hannula MJ, Myöhänen TT: Inhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers. Neurosci Lett 2014, 583C:37-42.
• [25]Kim JD, Toda C, D'Agostino G, Zeiss CJ, DiLeone RJ, Elsworth JD, et al.: Hypothalamic prolyl endopeptidase (PREP) regulates pancreatic insulin and glucagon secretion in mice. Proc Natl Acad Sci U S A 2014, 111(32):11876-81.
• [26]Tenorio-Laranga J, Männistö PT, García-Horsman JA: Hunting for peptide substrates of prolyl oligopeptidase: classical versus non-classical bioactive peptides. CNS Neurol Disord Drug Targets 2011, 10(3):319-26.
• [27]Tenorio-Laranga J, Männistö PT, Storvik M, Van der Veken P, García-Horsman JA: Four day inhibition of prolyl oligopeptidase causes significant changes in the peptidome of rat brain, liver and kidney. Biochimie 2012, 94(9):1849-59.
• [28]Klegeris A, Li J, Bammler TK, Jin J, Zhu D, Kashima DT, et al.: Prolyl endopeptidase is revealed following SILAC analysis to be a novel mediator of human microglial and THP-1 cell neurotoxicity. Glia 2008, 56(6):675-85.
• [29]O'Reilly P, Jackson PL, Noerager B, Parker S, Dransfield M, Gaggar A, et al.: N-alpha-PGP and PGP, potential biomarkers and therapeutic targets for COPD. Respir Res 2009, 10:38. BioMed Central Full Text
• [30]Overbeek SA, Braber S, Koelink PJ, Henricks PA, Mortaz E, LoTam Loi AT, et al.: Cigarette smoke-induced collagen destruction; key to chronic neutrophilic airway inflammation? PLoS One 2013, 8(1):e55612.
• [31]Aoyagi T, Wada T, Kojima F, Nagai M, Okubo M, Masaki Y, et al.: Abnormality of the post-proline-cleaving enzyme activity in mice with systemic lupus erythematosus-like syndrome. J Appl Biochem 1985, 7(4–5):273-81.
• [32]Hagihara M, Ohhashi M, Nagatsu T: Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in mice with lupus erythematosus-like syndrome and in patients with lupus erythematosus and rheumatoid arthritis. Clin Chem 1987, 33(8):1463-5.
• [33]Gotoh H, Hagihara M, Nagatsu T, Iwata H, Miura T: Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Clin Chem 1989, 35(6):1016-8.
• [34]Ito A, Hagihara M, Nagatsu T, Iwata H, Miura T: Collagenase-like (CL) peptidase activity in synovial fluid from patients with rheumatoid arthritis. Clin Chim Acta 1987, 170(2–3):291-6.
• [35]Kamori M, Hagihara M, Nagatsu T, Iwata H, Miura T: Activities of dipeptidyl peptidase II, dipeptidyl peptidase IV, prolyl endopeptidase, and collagenase-like peptidase in synovial membrane from patients with rheumatoid arthritis and osteoarthritis. Biochem Med Metab Biol 1991, 45(2):154-60.
• [36]Hardison MT, Galin FS, Calderon CE, Djekic UV, Parker SB, Wille KM, et al.: The presence of a matrix-derived neutrophil chemoattractant in bronchiolitis obliterans syndrome after lung transplantation. J Immunol 2009, 182(7):4423-31.
• [37]Tenorio-Laranga J, Coret-Ferrer F, Casanova-Estruch B, Burgal M, García-Horsman JA: Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis. J Neuroinflammation 2010, 7:23. BioMed Central Full Text
• [38]Lee SH, Fisher B: Portacaval shunt in the rat. Surgery 1961, 50:668-72.
• [39]Cauli O, Rodrigo R, Piedrafita B, Llansola M, Mansouri MT, Felipo V: Neuroinflammation contributes to hypokinesia in rats with hepatic encephalopathy. Ibuprofen restores its motor activity. J Neurosci Res 2009, 87(6):1369-74.
• [40]Montoliu C, Kosenko E, del Olmo JA, Serra MA, Rodrigo JM, Felipo V: Correlation of nitric oxide and atrial natriuretic peptide changes to altered cGMP homeostasis in liver cirrhosis. Liver Int 2005, 25:787-79.
• [41]Montoliu C, Piedrafita B, Serra MA, del Olmo JA, Ferrandez A, Rodrigo JM, et al.: Activation of soluble guanylate cyclase by nitric oxide in lymphocytes correlates with minimal hepatic encephalopathy in cirrhotic patients. J Mol Med 2007, 85(3):237-45.
• [42]Felipo V, Urios A, Montesinos E, Molina I, Garcia-Torres ML, Civera M, et al.: Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy. Metab Brain Dis 2012, 27(1):51-8.
• [43]Montoliu C, Rodrigo R, Monfort P, Llansola M, Cauli O, Boix J, et al.: Cyclic GMP pathways in hepatic encephalopathy. Neurological and therapeutic implications. Metab Brain Dis 2010, 25(1):39-48.
• [44]Butterworth RF: The liver-brain axis in liver failure: neuroinflammation and encephalopathy. Nat Rev Gastroenterol Hepatol 2013, 10(9):522-8.
• [45]Braber S, Koelink PJ, Henricks PA, Jackson PL, Nijkamp FP, Garssen J, et al.: Cigarette smoke-induced lung emphysema in mice is associated with prolyl endopeptidase, an enzyme involved in collagen breakdown. Am J Physiol Lung Cell Mol Physiol 2011, 300(2):L255-65.
• [46]Chu X, Ci X, He J, Jiang L, Wei M, Cao Q, et al.: Effects of a natural prolyl oligopeptidase inhibitor, rosmarinic acid, on lipopolysaccharide-induced acute lung injury in mice. Molecules 2012, 17(3):3586-98.
• [47]Gaggar A, Jackson PL, Noerager BD, O'Reilly PJ, McQuaid DB, Rowe SM, et al.: A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol 2008, 180(8):5662-9.
• [48]Kakegawa H, Matano Y, Inubushi T, Katunuma N: Significant accumulations of cathepsin B and prolylendopeptidase in inflammatory focus of delayed-type hypersensitivity induced by Mycobacterium tuberculosis in mice. Biochem Biophys Res Commun 2004, 316(1):78-84.
• [49]O'Reilly PJ, Hardison MT, Jackson PL, Xu X, Snelgrove RJ, Gaggar A, et al.: Neutrophils contain prolyl endopeptidase and generate the chemotactic peptide, PGP, from collagen. J Neuroimmunol 2009, 217(1–2):51-4.
• [50]Cavasin MA, Rhaleb NE, Yang XP, Carretero OA: Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP. Hypertension 2004, 43(5):1140-5.
• [51]Myöhänen TT, Tenorio-Laranga J, Jokinen B, Vazquez-Sanchez R, Moreno-Baylach M, García-Horsman JA, et al.: Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner. Br J Pharmacol 2011, 163(8):1666-78.
• [52]Peng H, Carretero OA, Raij L, Yang F, Kapke A, Rhaleb NE: Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats. Hypertension 2001, 37(2):794-800.
• [53]Gimenez-Garzó C, Urios A, Agustí A, González-López O, Escudero-García D, Escudero-Sanchis A, et al.: Is cognitive impairment in cirrhotic patients due to increased peroxynitrite and oxidative stress? Antioxid Redox Signal 2015, 22(10):871-7.
• [54]Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al.: Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterol 2003, 124(1):91-6.
• [55]Hermenegildo C, Montoliu C, Llansola M, Muñoz MD, Gaztelu JM, Miñana MD, et al.: Chronic hyperammonemia impairs glutamate-nitric oxide-cyclic GMP pathway in cerebellar neurons in culture and in the rat in vivo. Eur J Neurosci. 1998, 10:3201-9.
• [56]Belghiti M, Estevez-Herrera J, Gimenez-Garzo C, Gonzalez-Usano A, Montoliu C, Ferrer-Montiel A, et al.: Potentiation of the transient receptor potential vanilloid 1 channel contributes to pruritogenesis in a rat model of liver disease. J Biol Chem 2013, 288(14):9675-85.
• [57]Odeh M, Sabo E, Srugo I, Oliven A: Serum levels of tumor necrosis factor-alpha correlate with severity of hepatic encephalopathy due to chronic liver failure. Liver Int 2004, 24(2):110-6.
• [58]Odeh M, Sabo E, Srugo I, Oliven A: Relationship between tumor necrosis factor-alpha and ammonia in patients with hepatic encephalopathy due to chronic liver failure. Ann Intern Med 2005, 37(8):603-12.